Published in Cancer Weekly, May 31st, 2011
"The objective of the study was to describe the development and testing of the PSEFSM instrument. The PSEFSM instrument was incorporated into 2 randomized controlled trials for secondary analysis (N = 298): 63 persons with lung cancer and 235 persons with other cancer diagnoses undergoing a course of chemotherapy. Evidence for construct validity and generalizability was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.